Category Archives: Biotechnology

Sutro Biopharma Inc (STRO) is near the top in its industry group according to InvestorsObserver. STRO gets an overall rating of 65. That means it scores higher than 65 percent of stocks. Sutro Biopharma Inc gets a 81 rank in the Biotechnology industry. Biotechnology is number 35 out of 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 65 would rank higher than 65 percent of all stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Sutro Biopharma Inc (STRO) stock is trading at $16.67 as of 12:19 PM on Thursday, Dec 3, a gain of $0.32, or 1.96% from the previous closing price of $16.35. The stock has traded between $16.23 and $17.59 so far today. Volume today is 309,465 compared to average volume of 322,449.

Click Here to get the full Stock Score Report on Sutro Biopharma Inc (STRO) Stock.

Go here to see the original:
Is Sutro Biopharma Inc (STRO) the Top Pick in the Biotechnology Industry? - InvestorsObserver

Biotechnology has experienced extraordinary growth in recent times and came to popular attention as companies raced to find vaccines and cures for COVID-19. While investing in this area has obvious appeal from a social and moral perspective, it can also be a highly lucrative space as a growth investment in a portfolio.

Biotechnology specifically refers to technologies that use biological processes, capturing companies that focus on research, development, manufacturing and/or marketing of products based on biological and genetic information. The different types of biotechnology include biological drugs, vaccines, immunotherapy, gene therapy, orphan drugs and genetic engineering.

Biotechnology is predicted to be valued at more than US$833.34bn by 2027, compared to US$447.92 billion at the end of 2019, and will continue to grow, driven by the growing global population and the need for affordable, effective treatments and vaccines.Biotechnology will also be a beneficiary of population aging, particularly in Western countries. The reason for this is that an increase in the volume of older citizens is likely to have an accompanying and proportional increase in the volume of age-related diseases such as cardiovascular disease, dementia or arthritis, all requiring treatment.

Gilead is one example of a company with prospects in this space. Gilead is already well-known for its highly effective HIV treatments but is also targeting US and European approvals to market a drug called Filgotinib to treat rheumatoid arthritis.

In a demonstration of the growth in this industry, this year alone, 30-35 biotechnology companies are anticipated to go public, raising approximately US$3.5 billion.

The healthcare sector as a whole is likely to see greater investment as a result of the COVID-19 pandemic. For example, national health spending growth in the US is expected to average 5.4% annually through 2028, reaching US$6 trillion a year. Biotechnology will also be a beneficiary of this increased investment.

Investment and value from biotechnology is expected to grow in the coming years. While the trend already existed due to continuous tech improvements and the needs of a growing population, the COVID-19 pandemic has created a new spotlight on this area which may accelerate its growth.

Australian investors are likely to already be exposed to this growth segment in the concentrated domestic market. However, they may be missing exposure to the US, which dominates the global market for biotechnology.

Biotechnology could be considered part of a sector allocation to healthcare, or investors might view it as a thematic investment. You can find more information about thematic investing and using it in your portfolio in our latest whitepaper.

There are a range of ways to access the biotechnology industry.Investors could consider direct shares in biotechnology companies or alternatively consider managed funds. Direct shares can be a high-risk approach due to the high failure rates of drug testing and long periods of development (i.e., long periods where there may be no or a limited return on investment). Theres also the element of chance has the investor picked the winner? It could take years to know.

Managed investments, be it actively managed funds or passive options like ETFs, can assist in managing risk by spreading it across a larger number of companies. Investors could choose to invest by taking a sector approach and investing in a fund focusing on broader healthcare, or look at industry-specific options focusing on biotechnology. ETFS S&P Biotech ETF (ASX Code: CURE) is one such example that offers broad exposure to US biotechnology.

The rest is here:
The vaccines of tomorrow: how to invest in biotechnology - Rask Media

Maharashtra

DistrictCases

Mumbai45,478

Thane13,660

Pune9,920

Mumbai Suburban5,363

Aurangabad1,974

Nashik1,575

Raigad1,462

Palghar1,421

Solapur1,291

Jalgaon1,039

Akola757

Nagpur692

Kolhapur646

Satara629

Ratnagiri350

Amravati291

Dhule228

Hingoli208

Jalna201

Ahmednagar190

Nanded176

Yavatmal150

Sangli145

Latur139

Osmanabad125

Sindhudurg114

Buldhana88

Parbhani78

gondia69

Beed54

Nandurbar42

Gadchiroli42

Bhandara41

Chandrapur32

Washim13

Wardha11

18,52,266 4,757

81,162 2,769

17,23,370 7,486

47,734 40

DistrictCases

Udupi1,176

Kalaburagi669

Yadgir538

Bengaluru Urban529

Raichur369

Mandya346

Belagavi337

Bidar219

Hassan205

Davangere204

Vijayapura201

Dakshina Kannada179

Chikkaballapura149

Mysuru107

Bagalkote103

Uttara Kannada95

Shivamogga67

Dharwad61

Ballari60

Gadag45

Bengaluru Rural40

Tumakuru36

Kolar29

Haveri24

Chikkamagaluru19

Chitradurga14

Koppal5

Kodagu4

Ramanagara3

Chamarajanagara0

8,93,006 1,321

25,400 422

8,55,750 889

11,856 10

DistrictCases

Kurnool795

Krishna557

Guntur511

Anantapur428

East Godavari356

Chittoor319

Sri Potti Sriramulu Nell*296

Y.S.R.205

West Godavari199

Srikakulam183

Prakasam104

Visakhapatnam103

Vizianagaram23

8,71,972 667

5,910 256

8,59,029 914

7,033 9

DistrictCases

Chennai23,324

Chengalpattu1,314

Thiruvallur774

Villupuram509

See the article here:
Department Of Biotechnology's Expert Committee Tracking Developments Related To COVID-19 Vaccine: Official | News - Swachh India NDTV

Market Study Report, LLC adds latest research report on Food Biotechnology Industry Market, which delivers a comprehensive study on current industry trends. The outcome also includes revenue forecasts, statistics, market valuations which illustrates its growth trends and competitive landscape as well as the key players in the business.

This Food Biotechnology Industry market research study is a collection of insights that translate into a gist of this industry. It is explained in terms of a plethora of factors, some of which include the present scenario of this marketplace in tandem with the industry scenario over the forecast timeframe.

Request a sample Report of Food Biotechnology Industry Market at:https://www.marketstudyreport.com/request-a-sample/2727907?utm_source=cheshire.media&utm_medium=Ram

The report is also inclusive of some of the major development trends that characterize the Food Biotechnology Industry market. A comprehensive document in itself, the Food Biotechnology Industry market research study also contains numerous other pointers such as the current industry policies in conjunction with the topographical industry layout characteristics. Also, the Food Biotechnology Industry market study is comprised of parameters such as the impact of the current market scenario on investors.

The pros and cons of the enterprise products, a detailed scientific analysis pertaining to the raw material as well as industry downstream buyers, in conjunction with a gist of the enterprise competition trends are some of the other aspects included in this report.

How has the competitive landscape of this industry been categorized?

, as per the report.

Regional landscape: How will the details provided in the report help prominent stakeholders?

Ask for Discount on Food Biotechnology Industry Market Report at:https://www.marketstudyreport.com/check-for-discount/2727907?utm_source=cheshire.media&utm_medium=Ram

Other pivotal aspects encompassed in the Food Biotechnology Industry market study:

.

.

For More Details On this Report: https://www.marketstudyreport.com/reports/covid-19-outbreak-global-food-biotechnology-industry-market-report-development-trends-threats-opportunities-and-competitive-landscape-in-2020

Related Reports:

1. Global Sales Forecasting Software Market Report 2020 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2026 (Based on 2020 COVID-19 Worldwide Spread)Read More: https://www.marketstudyreport.com/reports/global-sales-forecasting-software-market-report-2020-by-key-players-types-applications-countries-market-size-forecast-to-2026-based-on-2020-covid-19-worldwide-spread

2. Global Application Performance Monitoring (APM) Suites Market Report 2020 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2026 (Based on 2020 COVID-19 Worldwide Spread)Read More: https://www.marketstudyreport.com/reports/global-application-performance-monitoring-apm-suites-market-report-2020-by-key-players-types-applications-countries-market-size-forecast-to-2026-based-on-2020-covid-19-worldwide-spread

Read More Reports On: https://www.marketwatch.com/press-release/copper-chlorophyll-market-segmented-by-product-top-manufacturers-geography-trends-forecasts-to-2025-2020-12-03

Contact Us:Corporate Sales,Market Study Report LLCPhone: 1-302-273-0910Toll Free: 1-866-764-2150 Email: [emailprotected]

See the original post:
Food Biotechnology Industry Market Growth Projection from 2020 to 2026 - Cheshire Media

The 62 rating InvestorsObserver gives to Agenus Inc (AGEN) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 76 percent of stocks in the Biotechnology industry, AGENs 62 overall rating means the stock scores better than 62 percent of all stocks.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Agenus Inc (AGEN) stock is down -1.52% while the S&P 500 is higher by 0.15% as of 12:22 PM on Thursday, Dec 3. AGEN is down -$0.06 from the previous closing price of $3.63 on volume of 1,217,123 shares. Over the past year the S&P 500 has risen 18.04% while AGEN is down -9.14%. AGEN lost -$1.09 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Agenus Inc (AGEN) Stock.

View original post here:
Where Does Agenus Inc (AGEN) Stock Fall in the Biotechnology Field? - InvestorsObserver

How far off is Universal Vision Biotechnology Co., Ltd. (GTSM:3218) from its intrinsic value? Using the most recent financial data, we'll take a look at whether the stock is fairly priced by taking the forecast future cash flows of the company and discounting them back to today's value. Our analysis will employ the Discounted Cash Flow (DCF) model. Before you think you won't be able to understand it, just read on! It's actually much less complex than you'd imagine.

Companies can be valued in a lot of ways, so we would point out that a DCF is not perfect for every situation. If you still have some burning questions about this type of valuation, take a look at the Simply Wall St analysis model.

View our latest analysis for Universal Vision Biotechnology

We are going to use a two-stage DCF model, which, as the name states, takes into account two stages of growth. The first stage is generally a higher growth period which levels off heading towards the terminal value, captured in the second 'steady growth' period. To start off with, we need to estimate the next ten years of cash flows. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.

A DCF is all about the idea that a dollar in the future is less valuable than a dollar today, so we need to discount the sum of these future cash flows to arrive at a present value estimate:

("Est" = FCF growth rate estimated by Simply Wall St)Present Value of 10-year Cash Flow (PVCF) = NT$10.0b

After calculating the present value of future cash flows in the initial 10-year period, we need to calculate the Terminal Value, which accounts for all future cash flows beyond the first stage. The Gordon Growth formula is used to calculate Terminal Value at a future annual growth rate equal to the 5-year average of the 10-year government bond yield of 0.9%. We discount the terminal cash flows to today's value at a cost of equity of 6.6%.

Terminal Value (TV)= FCF2030 (1 + g) (r g) = NT$1.7b (1 + 0.9%) (6.6% 0.9%) = NT$31b

Present Value of Terminal Value (PVTV)= TV / (1 + r)10= NT$31b ( 1 + 6.6%)10= NT$16b

The total value is the sum of cash flows for the next ten years plus the discounted terminal value, which results in the Total Equity Value, which in this case is NT$26b. The last step is to then divide the equity value by the number of shares outstanding. Relative to the current share price of NT$286, the company appears about fair value at a 17% discount to where the stock price trades currently. The assumptions in any calculation have a big impact on the valuation, so it is better to view this as a rough estimate, not precise down to the last cent.

Now the most important inputs to a discounted cash flow are the discount rate, and of course, the actual cash flows. You don't have to agree with these inputs, I recommend redoing the calculations yourself and playing with them. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Universal Vision Biotechnology as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 6.6%, which is based on a levered beta of 0.800. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.

Valuation is only one side of the coin in terms of building your investment thesis, and it is only one of many factors that you need to assess for a company. It's not possible to obtain a foolproof valuation with a DCF model. Preferably you'd apply different cases and assumptions and see how they would impact the company's valuation. For example, changes in the company's cost of equity or the risk free rate can significantly impact the valuation. For Universal Vision Biotechnology, we've put together three further elements you should further research:

PS. Simply Wall St updates its DCF calculation for every Taiwanese stock every day, so if you want to find the intrinsic value of any other stock just search here.

PromotedIf you decide to trade Universal Vision Biotechnology, use the lowest-cost* platform that is rated #1 Overall by Barrons, Interactive Brokers. Trade stocks, options, futures, forex, bonds and funds on 135 markets, all from a single integrated account.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. *Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.

The rest is here:
Estimating The Fair Value Of Universal Vision Biotechnology Co., Ltd. (GTSM:3218) - Simply Wall St